vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and TRIO-TECH INTERNATIONAL (TRT). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $15.6M, roughly 1.2× TRIO-TECH INTERNATIONAL). TRIO-TECH INTERNATIONAL runs the higher net margin — 0.8% vs -177.4%, a 178.2% gap on every dollar of revenue. On growth, TRIO-TECH INTERNATIONAL posted the faster year-over-year revenue change (81.6% vs -11.5%). TRIO-TECH INTERNATIONAL produced more free cash flow last quarter ($-152.0K vs $-23.1M). Over the past eight quarters, TRIO-TECH INTERNATIONAL's revenue compounded faster (22.7% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Trio-Tech International is a global provider of semiconductor testing and burn-in solutions, alongside specialized manufacturing services for electronic components. It serves clients across the semiconductor, aerospace, and consumer electronics sectors, with operational footprints spanning North America, Asia, and Europe, delivering custom reliability testing systems and related support services.

LAB vs TRT — Head-to-Head

Bigger by revenue
LAB
LAB
1.2× larger
LAB
$19.6M
$15.6M
TRT
Growing faster (revenue YoY)
TRT
TRT
+93.0% gap
TRT
81.6%
-11.5%
LAB
Higher net margin
TRT
TRT
178.2% more per $
TRT
0.8%
-177.4%
LAB
More free cash flow
TRT
TRT
$22.9M more FCF
TRT
$-152.0K
$-23.1M
LAB
Faster 2-yr revenue CAGR
TRT
TRT
Annualised
TRT
22.7%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
LAB
LAB
TRT
TRT
Revenue
$19.6M
$15.6M
Net Profit
$-34.7M
$126.0K
Gross Margin
48.5%
16.0%
Operating Margin
-168.5%
0.6%
Net Margin
-177.4%
0.8%
Revenue YoY
-11.5%
81.6%
Net Profit YoY
-28.8%
-75.1%
EPS (diluted)
$-0.09
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
TRT
TRT
Q4 25
$15.6M
Q3 25
$19.6M
$15.5M
Q2 25
$21.8M
$10.7M
Q1 25
$40.8M
$7.4M
Q4 24
$8.6M
Q3 24
$22.1M
$9.8M
Q2 24
$22.5M
$9.7M
Q1 24
$45.5M
$10.4M
Net Profit
LAB
LAB
TRT
TRT
Q4 25
$126.0K
Q3 25
$-34.7M
$77.0K
Q2 25
$-33.5M
$183.0K
Q1 25
$-26.0M
$-495.0K
Q4 24
$507.0K
Q3 24
$-26.9M
$-236.0K
Q2 24
$-45.7M
$243.0K
Q1 24
$-32.2M
$70.0K
Gross Margin
LAB
LAB
TRT
TRT
Q4 25
16.0%
Q3 25
48.5%
16.7%
Q2 25
48.8%
24.6%
Q1 25
48.4%
26.8%
Q4 24
25.7%
Q3 24
54.9%
23.7%
Q2 24
46.1%
27.5%
Q1 24
53.1%
26.0%
Operating Margin
LAB
LAB
TRT
TRT
Q4 25
0.6%
Q3 25
-168.5%
0.3%
Q2 25
-118.1%
4.4%
Q1 25
-80.8%
-4.6%
Q4 24
-0.0%
Q3 24
-120.9%
1.4%
Q2 24
-134.5%
3.7%
Q1 24
-132.2%
0.6%
Net Margin
LAB
LAB
TRT
TRT
Q4 25
0.8%
Q3 25
-177.4%
0.5%
Q2 25
-153.7%
1.7%
Q1 25
-63.8%
-6.7%
Q4 24
5.9%
Q3 24
-122.0%
-2.4%
Q2 24
-203.3%
2.5%
Q1 24
-70.6%
0.7%
EPS (diluted)
LAB
LAB
TRT
TRT
Q4 25
$0.01
Q3 25
$-0.09
$0.02
Q2 25
$-0.09
$0.11
Q1 25
$-0.07
$-0.12
Q4 24
$0.06
Q3 24
$-0.07
$-0.06
Q2 24
$-0.12
$0.05
Q1 24
$-0.27
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
TRT
TRT
Cash + ST InvestmentsLiquidity on hand
$129.4M
$16.5M
Total DebtLower is stronger
$581.0K
Stockholders' EquityBook value
$399.7M
$33.5M
Total Assets
$539.6M
$45.7M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
TRT
TRT
Q4 25
$16.5M
Q3 25
$129.4M
$17.4M
Q2 25
$158.6M
$16.7M
Q1 25
$150.9M
$17.6M
Q4 24
$16.5M
Q3 24
$210.6M
$15.5M
Q2 24
$269.8M
$16.5M
Q1 24
$287.1M
$17.0M
Total Debt
LAB
LAB
TRT
TRT
Q4 25
$581.0K
Q3 25
$622.0K
Q2 25
$684.0K
Q1 25
$729.0K
Q4 24
$782.0K
Q3 24
$55.2M
$923.0K
Q2 24
$55.1M
$874.0K
Q1 24
$55.0M
$984.0K
Stockholders' Equity
LAB
LAB
TRT
TRT
Q4 25
$33.5M
Q3 25
$399.7M
$34.1M
Q2 25
$424.5M
$34.0M
Q1 25
$454.6M
$32.3M
Q4 24
$31.8M
Q3 24
$489.3M
$33.1M
Q2 24
$510.3M
$31.3M
Q1 24
$577.3M
$31.2M
Total Assets
LAB
LAB
TRT
TRT
Q4 25
$45.7M
Q3 25
$539.6M
$47.4M
Q2 25
$557.0M
$41.1M
Q1 25
$579.6M
$40.0M
Q4 24
$39.8M
Q3 24
$681.5M
$42.9M
Q2 24
$708.7M
$42.5M
Q1 24
$777.7M
$43.1M
Debt / Equity
LAB
LAB
TRT
TRT
Q4 25
0.02×
Q3 25
0.02×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.11×
0.03×
Q2 24
0.11×
0.03×
Q1 24
0.10×
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
TRT
TRT
Operating Cash FlowLast quarter
$-22.2M
$134.0K
Free Cash FlowOCF − Capex
$-23.1M
$-152.0K
FCF MarginFCF / Revenue
-118.1%
-1.0%
Capex IntensityCapex / Revenue
4.5%
1.8%
Cash ConversionOCF / Net Profit
1.06×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$137.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
TRT
TRT
Q4 25
$134.0K
Q3 25
$-22.2M
$933.0K
Q2 25
$-20.7M
$-664.0K
Q1 25
$-30.3M
$781.0K
Q4 24
$2.1M
Q3 24
$-27.9M
$-1.9M
Q2 24
$-39.0M
$199.0K
Q1 24
$-62.5M
$1.2M
Free Cash Flow
LAB
LAB
TRT
TRT
Q4 25
$-152.0K
Q3 25
$-23.1M
$887.0K
Q2 25
$-22.6M
$-1.2M
Q1 25
$-35.3M
$623.0K
Q4 24
$1.9M
Q3 24
$-30.1M
$-1.9M
Q2 24
$-41.0M
$-135.0K
Q1 24
$-63.3M
$1.1M
FCF Margin
LAB
LAB
TRT
TRT
Q4 25
-1.0%
Q3 25
-118.1%
5.7%
Q2 25
-103.6%
-11.4%
Q1 25
-86.6%
8.4%
Q4 24
22.4%
Q3 24
-136.4%
-19.7%
Q2 24
-182.2%
-1.4%
Q1 24
-138.9%
10.6%
Capex Intensity
LAB
LAB
TRT
TRT
Q4 25
1.8%
Q3 25
4.5%
0.3%
Q2 25
8.7%
5.2%
Q1 25
12.4%
2.1%
Q4 24
2.1%
Q3 24
10.2%
0.7%
Q2 24
8.6%
3.4%
Q1 24
1.7%
0.5%
Cash Conversion
LAB
LAB
TRT
TRT
Q4 25
1.06×
Q3 25
12.12×
Q2 25
-3.63×
Q1 25
Q4 24
4.16×
Q3 24
Q2 24
0.82×
Q1 24
16.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

TRT
TRT

Semiconductor Backend Solutions$12.4M79%
Industrial Electronics$3.3M21%

Related Comparisons